Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Corbus Pharmaceuticals Holdings Cash Ratio?
Corbus Pharmaceuticals HoldingsLTS:0SZI +0.09%30 Cash Ratio is 5.49 as of Jun. 2026, which is 16% above its 10-year median of 4.75. GuruFocus rates LTS:0SZI with a GF Score™ of 30/100 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,341 Biotechnology companies, Corbus Pharmaceuticals Holdings ranks better than 65.85% on this metric.
Corbus Pharmaceuticals Holdings has a Cash Ratio of 5.49. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Corbus Pharmaceuticals Holdings's Cash Ratio or its related term are showing as below:
LTS:0SZI'
s Cash Ratio Range Over the Past 10 Years
Min: 0.66 Med: 4.75 Max: 13.71
Current: 5.49
During the past 13 years, Corbus Pharmaceuticals Holdings's highest Cash Ratio was 13.71. The lowest was 0.66. And the median was 4.75.
LTS:0SZI's Cash Ratio is ranked better than 65.85% of 1341
companies
in the Biotechnology industry
Industry Median: 3
vs LTS:0SZI: 5.49
Corbus Pharmaceuticals Holdings (LTS:0SZI) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Corbus Pharmaceuticals Holdings Cash Ratio Related Terms
Corbus Pharmaceuticals Holdings Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0SZI vs OKUR, HUMA, TNYA: Cash Ratio Comparison
For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corbus Pharmaceuticals Holdings Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Corbus Pharmaceuticals Holdings's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corbus Pharmaceuticals Holdings (LTS:0SZI) has a Cash Ratio of 5.49 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Corbus Pharmaceuticals Holdings and its competitors. This is 16% above median its historical median of 4.75. Over the past decade, Corbus Pharmaceuticals Holdings' Cash Ratio has ranged from 0.66 to 13.71. According to the industry distribution chart, Corbus Pharmaceuticals Holdings ranks #458 out of 1341 companies in the Biotechnology industry, placing it in the top 34.2%.
Is Corbus Pharmaceuticals Holdings' Cash Ratio too high?
Corbus Pharmaceuticals Holdings' current Cash Ratio of 5.49 is 16% above median its 10-year median of 4.75. Over the past 10 years, this metric has ranged from a low of 0.66 to a high of 13.71. The Biotechnology industry median Cash Ratio is 3.00. Corbus Pharmaceuticals Holdings' value of 5.49 is 83% above this industry median. Based on the distribution chart, Corbus Pharmaceuticals Holdings ranks #458 out of 1341 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Corbus Pharmaceuticals Holdings has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corbus Pharmaceuticals Holdings' Cash Ratio compare to OKUR and HUMA?
According to the Biotechnology industry distribution chart, Corbus Pharmaceuticals Holdings ranks #458 out of 1341 companies for Cash Ratio. This puts Corbus Pharmaceuticals Holdings in the upper half of its industry. The industry median Cash Ratio is 3.00. Corbus Pharmaceuticals Holdings' value of 5.49 is 83% above this benchmark. Historically, Corbus Pharmaceuticals Holdings' own Cash Ratio has ranged from 0.66 to 13.71 over the past decade. While the company's 10-year median is 4.75 vs. the industry median of 3.00, Corbus Pharmaceuticals Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 3.00, based on 1,341 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corbus Pharmaceuticals Holdings's current Cash Ratio of 5.49 is 83% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Corbus Pharmaceuticals Holdings and its competitors. For the Biotechnology industry, the median Cash Ratio is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corbus Pharmaceuticals Holdings's current Cash Ratio is 5.49, which is 16% above median its own 10-year median of 4.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corbus Pharmaceuticals Holdings stock overvalued right now?
Based on GuruFocus' analysis, Corbus Pharmaceuticals Holdings (LTS:0SZI) is currently considered Significantly Overvalued. The current Cash Ratio is 5.49, which is 16% above median its 10-year median of 4.75 and 83% above the Biotechnology industry median of 3.00. Corbus Pharmaceuticals Holdings' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Corbus Pharmaceuticals Holdings (LTS:0SZI), the current Cash Ratio is 5.49 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
30GF Score
Get the complete analysis for LTS:0SZI
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0SZI has been successfully added to your 
